Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22233748 | 0.98 | POLB (0.46) | POLBOPRM1ATMALDH1A1ALOX15 | |
| Trifluoroacetic Acid SCHEMBL18740356 | 0.87 | POLB (0.39) | POLBOPRM1ATMALDH1A1ALOX15 | |
| SCHEMBL24094554 | 0.84 | OPRM1 (0.47) | POLBOPRM1ATMALDH1A1ALOX15 | |
| SCHEMBL2811875 | 0.81 | OPRM1 (0.42) | POLBOPRM1ATMALDH1A1ALOX15 | |
| SCHEMBL1963692 | 0.80 | BRD4 (0.47) | POLBOPRM1ATMALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL25271505 | 0.78 | BRD4 (0.46) | POLBOPRM1ATMALDH1A1ALOX15 | |
| SCHEMBL2814112 | 0.78 | OPRM1 (0.54) | POLBOPRM1ALDH1A1ALOX15KDM4E | |
| SCHEMBL18134201 | 0.78 | ALDH1A1 (0.46) | POLBOPRM1ATMALDH1A1ALOX15 | |
| SCHEMBL69496 | 0.78 | ALDH1A1 (0.46) | POLBOPRM1ATMALDH1A1ALOX15 | |
| SCHEMBL14010820 | 0.77 | OPRM1 (0.42) | POLBOPRM1ATMALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024263753-A1 | SULFOXIMINE BASED STT3A/B MODULATORS FOR THE TREATMENT OF DISEASE | Vir Biotechnology, Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20230026696-A1 | TRPV4 RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-26 | — | — | US | disclosed |
| WO-2021102314-A1 | TRPV4 RECEPTOR LIGANDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2017063755-A1 | CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017063756-A1 | CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS AS PIN1 MODULATORS | POLYPHOR AG (CH) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017063754-A1 | CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS AS PIN1 MODULATORS | POLYPHOR AG (CH) | 2017-04-20 | — | — | WO | disclosed |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| EP-2081888-A1 | N-BIARYL (HETERO) ARYLSULPHONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY LYMPHOCYTES INTERACTIONS | Novartis AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008028937-A1 | N-BIARYL (HETERO) ARYLSULPHONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY LYMPHOCYTES INTERACTIONS | NOVARTIS AG (CH) | 2008-03-13 | — | — | WO | disclosed |
| WO-2006043149-A9 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET SOC CIV (FR) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006043149-A2 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET (FR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | S1PR2, S1PR1, S1PR5 | POLB 4135/4885OPRM1 1840/4885ATM 2939/4885 |
| US-20230026696-A1 | TRPV4 RECEPTOR LIGANDS | TRPV4, TRPV2, TRPV3 | POLB 4847/4885OPRM1 212/4885ATM 4206/4885 |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | UGT2B7, CYP3A7, STS | POLB 3791/4885OPRM1 2285/4885ATM 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.